Avid Bioservices Inc (CDMO)

[biopharm]

That may lead to SURPRISING Effects because in a median table a few eventing early doesn't weight in. A median table can have big gaps, say some eventing at 5 months and the next one at 10 month, then one at 11 months and the MOS would still be 10 months with a 5-11 window. And that a median is used vs an average is a good thing for Bavituximab in this case IF healthier patients suffer less or not at all from the Bavi latency.

CP, this "median" being used for Bavituximab and I should have looked or known but unable to right now....

is this "median" something new to the Sunrise trial ... ? I was just trying to understand when this changed during the trials and was "median" used during the phase IIb NSCLC ...etc

I know, I was not prepared at all but I blame it on Pfizer picking up Allergan for at least $150 Billion. Brigitte Phan being #1 on the PAV list of the late Dr. Thorpe and all the departures from Peregrine that fled to Allergan still makes me remember them at times like this...

http://www.nytimes.com/2015/11/19/business/dealbook/pfizer-allergan-deal-for-up-to-150-billion-is-said-to-be-close-to-complete.html?_r=0